12 completed, 1 withdrawn. 13 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 12, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
Follow Cytomegalovirus Retinitis: new trials by email Literature Review of Cytomegalovirus Retinitis trials Research Report on Cytomegalovirus Retinitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT) MSL-109, Placebo - HIV Infections, Cytomegalovirus Retinitis | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 209 | 1995-09-01 | 2015-11-17 |
| Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis cidofovir - Cytomegalovirus Retinitis, Acquired Immunodeficiency Syndrome | Phase 2 | Completed | National Center for Research Resources (NCRR) | 90 | 1995-03-01 | 2005-06-24 |
| Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Cidofovir - HIV Infections, CMV Cytomegalovirus Retinitis | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 64 | 1994-04-01 | 2015-11-17 |
| A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir Foscarnet sodium - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-04 | ||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure Foscarnet sodium - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 156 | 2021-11-03 | |
| A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) Sevirumab - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 300 | 2012-10-25 | |
| The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes Fomivirsen sodium - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 2005-06-24 | ||
| Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS Sevirumab, Foscarnet sodium, Ganciclovir - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 167 | 2021-11-01 | |
| The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Cidofovir, Probenecid - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | Gilead Sciences | 48 | 2005-06-24 | |
| The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV Ganciclovir - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 850 | 2021-11-04 | |
| A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) Fomivirsen sodium, Ganciclovir - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 194 | 2005-06-24 | |
| A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis Nelfinavir mesylate - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | Agouron Pharmaceuticals | 2005-06-24 | ||
| CMV Retinitis Retreatment Trial Foscarnet sodium, Ganciclovir - Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 300 | 2011-03-01 |
HIV Infections (12) · Acquired Immunodeficiency Syndrome (10) · AIDS-Related Opportunistic Infections (6) · Multiple Acyl Coenzyme A Dehydrogenase Deficiency (6) · Cytomegalovirus Infections (5) · Retinitis (5) · Gastrointestinal Diseases (1) · Rare Diseases (1)
Blood-Borne Infections (13) · Communicable Diseases (13) · DNA Virus Infections (13) · Eye Diseases (13) · Eye Infections (13) · Eye Infections, Viral (13) · Genital Diseases (13) · Herpesviridae Infections (13) · Immune System Diseases (13) · Immunologic Deficiency Syndromes (13) · Infections (13) · Lentivirus Infections (13) · RNA Virus Infections (13) · Retinal Diseases (13) · Retroviridae Infections (13)
Foscarnet (4) · Ganciclovir (4) · Cidofovir (3) · sevirumab (3) · fomivirsen (2) · Antibodies, Monoclonal (1) · Nelfinavir (1) · Probenecid (1)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Ionis Pharmaceuticals, Inc. (2) · Johns Hopkins Bloomberg School of Public Health (2) · Agouron Pharmaceuticals (1) · Gilead Sciences (1) · National Center for Research Resources (NCRR) (1)
United States (9) · United Kingdom (1)
MA Jacobson (2) · Borucki M (1) · Brosgart C (1) · C Crumpacker (1) · CS Crumpacker (1) · Craig C (1) · David V. Weinberg (1) · Douglas Jabs, MD (1) · Gnann J (1) · Hirsch MS (1) · Pollard RB (1)
PMID 31042791, PMID 11919489, PMID 12232843, PMID 12559647, PMID 15498605, PMID 9400786